Amoéba

Amoéba is an innovative public company exploiting the unique properties of a naturally occurring amoeba, Willaertia magna C2c Maky, as a biocontrol agent. Its primary focus is on agricultural biocontrol, offering a natural alternative to chemical fungicides for diseases like mildew and powdery mildew, with additional R&D in water treatment and human health. The company is in a commercial expansion phase for its agricultural product, supported by recent capital raises, and faces opportunities and risks tied to the regulatory and adoption landscape for biological crop protection.

Proprietary platform based on the naturally occurring amoeba Willaertia magna C2c Maky. Its applications leverage different properties of the amoeba, primarily the fungicidal activity of its mechanically lysed form for agriculture and bactericidal activity for water treatment and potential health uses.

Amoéba competes in the rapidly growing biocontrol and biopesticide market, facing competition from both large agrochemical companies developing their own biological portfolios and numerous smaller biotech startups. Its differentiation lies in its unique, non-GMO amoeba-based mode of action, which it must prove is as effective, reliable, and cost-competitive as rival microbial or biochemical solutions.